1. Home
  2. ETON vs GSRT Comparison

ETON vs GSRT Comparison

Compare ETON & GSRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • GSRT
  • Stock Information
  • Founded
  • ETON 2017
  • GSRT 2023
  • Country
  • ETON United States
  • GSRT United States
  • Employees
  • ETON N/A
  • GSRT N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • GSRT
  • Sector
  • ETON Health Care
  • GSRT
  • Exchange
  • ETON Nasdaq
  • GSRT Nasdaq
  • Market Cap
  • ETON 388.3M
  • GSRT 324.1M
  • IPO Year
  • ETON 2018
  • GSRT 2024
  • Fundamental
  • Price
  • ETON $14.39
  • GSRT $10.41
  • Analyst Decision
  • ETON Strong Buy
  • GSRT
  • Analyst Count
  • ETON 3
  • GSRT 0
  • Target Price
  • ETON $29.67
  • GSRT N/A
  • AVG Volume (30 Days)
  • ETON 420.1K
  • GSRT 836.7K
  • Earning Date
  • ETON 08-07-2025
  • GSRT 01-01-0001
  • Dividend Yield
  • ETON N/A
  • GSRT N/A
  • EPS Growth
  • ETON N/A
  • GSRT N/A
  • EPS
  • ETON N/A
  • GSRT 0.14
  • Revenue
  • ETON $48,327,000.00
  • GSRT N/A
  • Revenue This Year
  • ETON $101.12
  • GSRT N/A
  • Revenue Next Year
  • ETON $45.71
  • GSRT N/A
  • P/E Ratio
  • ETON N/A
  • GSRT $73.38
  • Revenue Growth
  • ETON 40.88
  • GSRT N/A
  • 52 Week Low
  • ETON $3.25
  • GSRT $9.86
  • 52 Week High
  • ETON $21.48
  • GSRT $11.49
  • Technical
  • Relative Strength Index (RSI)
  • ETON 45.76
  • GSRT N/A
  • Support Level
  • ETON $13.78
  • GSRT N/A
  • Resistance Level
  • ETON $15.73
  • GSRT N/A
  • Average True Range (ATR)
  • ETON 0.75
  • GSRT 0.00
  • MACD
  • ETON -0.01
  • GSRT 0.00
  • Stochastic Oscillator
  • ETON 31.98
  • GSRT 0.00

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About GSRT GSR III Acquisition Corp. Ordinary Shares

GSR III Acquisition Corp is a blank check company.

Share on Social Networks: